These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 31633402)

  • 1. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules.
    Lv M; Liu Y; Ma S; Yu Z
    Future Med Chem; 2019 Oct; 11(19):2595-2620. PubMed ID: 31633402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.
    Xu X; Dai H; Wang C
    Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
    Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG
    Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.
    Spagnolo P; Kropski JA; Jones MG; Lee JS; Rossi G; Karampitsakos T; Maher TM; Tzouvelekis A; Ryerson CJ
    Pharmacol Ther; 2021 Jun; 222():107798. PubMed ID: 33359599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis.
    Nho RS
    Drug Dev Res; 2015 Nov; 76(7):343-53. PubMed ID: 26303294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Yarahmadi R; Ghaznavi H; Mehrzadi S
    Expert Opin Ther Targets; 2018 Dec; 22(12):1049-1061. PubMed ID: 30445883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
    Knipe RS; Tager AM; Liao JK
    Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin.
    Hosseinzadeh A; Javad-Moosavi SA; Reiter RJ; Hemati K; Ghaznavi H; Mehrzadi S
    Life Sci; 2018 May; 201():17-29. PubMed ID: 29567077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of 
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].
    Xiao T; Bao J; Liu X; Huang H; Zhou H
    Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):756-763. PubMed ID: 36167462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.
    Vaidya B; Patel R; Muth A; Gupta V
    Curr Med Chem; 2017; 24(22):2439-2458. PubMed ID: 28552057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.
    O'Riordan TG; Smith V; Raghu G
    Chest; 2015 Oct; 148(4):1083-1092. PubMed ID: 26020856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Senotherapeutics: Targeting senescence in idiopathic pulmonary fibrosis.
    Merkt W; Bueno M; Mora AL; Lagares D
    Semin Cell Dev Biol; 2020 May; 101():104-110. PubMed ID: 31879264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
    Bamberg A; Redente EF; Groshong SD; Tuder RM; Cool CD; Keith RC; Edelman BL; Black BP; Cosgrove GP; Wynes MW; Curran-Everett D; De Langhe S; Ortiz LA; Thorburn A; Riches DWH
    Am J Respir Crit Care Med; 2018 Oct; 198(7):914-927. PubMed ID: 29727583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review.
    Kinoshita T; Goto T
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].
    Liu C; He Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):695-700. PubMed ID: 32838491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catch your breath: The protective role of the angiotensin AT
    Young ON; Bourke JE; Widdop RE
    Biochem Pharmacol; 2023 Nov; 217():115839. PubMed ID: 37778444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis.
    Kou L; Kou P; Luo G; Wei S
    Oxid Med Cell Longev; 2022; 2022():6197219. PubMed ID: 35345828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.